APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemophilia A Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

22 December 2025195 pages

Choose your research edition.

Industry ResearchHemophilia A Drug Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemophilia A Drug Industry Growth and Trends Forecast to 2032115 pages · $3,450 USDMarket StructureGlobal Hemophilia A Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemophilia A Drug Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemophilia A Drug Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Hemophilia A Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Hemophilia A Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Hemophilia A Drug include Bayer AG, mAbxience SA, LFB SA, Immusoft Corp, Idogen AB, Green Cross Corp, Expression Therapeutics LLC, EpiVax Inc and Dimension Therapeutics Inc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Hemophilia A Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemophilia A Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemophilia A Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hemophilia A Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Hemophilia A Drug Segment by Company

Bayer AG

mAbxience SA

LFB SA

Immusoft Corp

Idogen AB

Green Cross Corp

Expression Therapeutics LLC

EpiVax Inc

Dimension Therapeutics Inc

DBV Technologies SA

CSL Ltd

Chugai Pharmaceutical Co Ltd

Catalyst Biosciences Inc

Bioverativ Inc

BioMarin Pharmaceutical Inc

Hemophilia A Drug Segment by Type

ATXF-8117

BAY-1093884

BIVV-001

BS-027125

Concizumab

CSL-689

Others

Hemophilia A Drug Segment by Application

Clinic

Hospital

ASCs

Hemophilia A Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemophilia A Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemophilia A Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemophilia A Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hemophilia A Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Hemophilia A Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Hemophilia A Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Hemophilia A Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Hemophilia A Drug Industry Trends Table 2. Hemophilia A Drug Industry Drivers Table 3. Hemophilia A Drug Industry Opportunities and Challenges Table 4. Hemophilia A Drug Industry Restraints Table 5. Global Hemophilia A Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Hemophilia A Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Hemophilia A Drug Sales by Manufacturers (k units) & (2021-2026) Table 8. Global Hemophilia A Drug Sales Market Share by Manufacturers Table 9. Global Hemophilia A Drug Average Sales Price (US$/unit) of Manufacturers (2021-2026) Table 10. Global Hemophilia A Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Hemophilia A Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Hemophilia A Drug Manufacturers, Product Type & Application Table 13. Global Hemophilia A Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Hemophilia A Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of ATXF-8117 Table 17. Major Manufacturers of BAY-1093884 Table 18. Major Manufacturers of BIVV-001 Table 19. Major Manufacturers of BS-027125 Table 20. Major Manufacturers of Concizumab Table 21. Major Manufacturers of CSL-689 Table 22. Major Manufacturers of Others Table 23. Global Hemophilia A Drug Sales by Type 2021 VS 2025 VS 2032 (k units) Table 24. Global Hemophilia A Drug Sales by Type (2021-2026) & (k units) Table 25. Global Hemophilia A Drug Sales by Type (2027-2032) & (k units) Table 26. Global Hemophilia A Drug Sales Market Share by Type (2021-2026) Table 27. Global Hemophilia A Drug Sales Market Share by Type (2027-2032) Table 28. Global Hemophilia A Drug Revenue by Type 2021 VS 2025 VS 2032 (k units) Table 29. Global Hemophilia A Drug Revenue by Type (2021-2026) & (k units) Table 30. Global Hemophilia A Drug Revenue by Type (2027-2032) & (k units) Table 31. Global Hemophilia A Drug Revenue Market Share by Type (2021-2026) Table 32. Global Hemophilia A Drug Revenue Market Share by Type (2027-2032) Table 33. Major Manufacturers of Clinic Table 34. Major Manufacturers of Hospital Table 35. Major Manufacturers of ASCs Table 36. Global Hemophilia A Drug Sales by Application 2021 VS 2025 VS 2032 (k units) Table 37. Global Hemophilia A Drug Sales by Application (2021-2026) & (k units) Table 38. Global Hemophilia A Drug Sales by Application (2027-2032) & (k units) Table 39. Global Hemophilia A Drug Sales Market Share by Application (2021-2026) Table 40. Global Hemophilia A Drug Sales Market Share by Application (2027-2032) Table 41. Global Hemophilia A Drug Revenue by Application 2021 VS 2025 VS 2032 (k units) Table 42. Global Hemophilia A Drug Revenue by Application (2021-2026) & (k units) Table 43. Global Hemophilia A Drug Revenue by Application (2027-2032) & (k units) Table 44. Global Hemophilia A Drug Revenue Market Share by Application (2021-2026) Table 45. Global Hemophilia A Drug Revenue Market Share by Application (2027-2032) Table 46. Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 47. Global Hemophilia A Drug Sales by Region (2021-2026) & (k units) Table 48. Global Hemophilia A Drug Sales Market Share by Region (2021-2026) Table 49. Global Hemophilia A Drug Sales Forecasted by Region (2027-2032) & (k units) Table 50. Global Hemophilia A Drug Sales Forecasted Market Share by Region (2027-2032) Table 51. North America Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 52. North America Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 53. North America Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 54. Europe Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 55. Europe Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 56. Europe Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 57. Asia Pacific Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 58. Asia Pacific Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 59. Asia Pacific Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 60. South America, Middle East and Africa Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k units) Table 61. South America, Middle East and Africa Hemophilia A Drug Sales by Country (2021-2026) & (k units) Table 62. South America, Middle East and Africa Hemophilia A Drug Sales by Country (2027-2032) & (k units) Table 63. Global Hemophilia A Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 64. Global Hemophilia A Drug Revenue by Region (2021-2026) & (US$ Million) Table 65. Global Hemophilia A Drug Revenue by Region (2027-2032) & (US$ Million) Table 66. Global Hemophilia A Drug Revenue Market Share by Region (2021-2026) Table 67. Global Hemophilia A Drug Revenue Market Share by Region (2027-2032) Table 68. Bayer AG Company Information Table 69. Bayer AG Business Overview Table 70. Bayer AG Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Bayer AG Hemophilia A Drug Product Portfolio Table 72. Bayer AG Recent Development Table 73. mAbxience SA Company Information Table 74. mAbxience SA Business Overview Table 75. mAbxience SA Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. mAbxience SA Hemophilia A Drug Product Portfolio Table 77. mAbxience SA Recent Development Table 78. LFB SA Company Information Table 79. LFB SA Business Overview Table 80. LFB SA Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. LFB SA Hemophilia A Drug Product Portfolio Table 82. LFB SA Recent Development Table 83. Immusoft Corp Company Information Table 84. Immusoft Corp Business Overview Table 85. Immusoft Corp Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Immusoft Corp Hemophilia A Drug Product Portfolio Table 87. Immusoft Corp Recent Development Table 88. Idogen AB Company Information Table 89. Idogen AB Business Overview Table 90. Idogen AB Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Idogen AB Hemophilia A Drug Product Portfolio Table 92. Idogen AB Recent Development Table 93. Green Cross Corp Company Information Table 94. Green Cross Corp Business Overview Table 95. Green Cross Corp Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Green Cross Corp Hemophilia A Drug Product Portfolio Table 97. Green Cross Corp Recent Development Table 98. Expression Therapeutics LLC Company Information Table 99. Expression Therapeutics LLC Business Overview Table 100. Expression Therapeutics LLC Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 101. Expression Therapeutics LLC Hemophilia A Drug Product Portfolio Table 102. Expression Therapeutics LLC Recent Development Table 103. EpiVax Inc Company Information Table 104. EpiVax Inc Business Overview Table 105. EpiVax Inc Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 106. EpiVax Inc Hemophilia A Drug Product Portfolio Table 107. EpiVax Inc Recent Development Table 108. Dimension Therapeutics Inc Company Information Table 109. Dimension Therapeutics Inc Business Overview Table 110. Dimension Therapeutics Inc Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 111. Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio Table 112. Dimension Therapeutics Inc Recent Development Table 113. DBV Technologies SA Company Information Table 114. DBV Technologies SA Business Overview Table 115. DBV Technologies SA Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 116. DBV Technologies SA Hemophilia A Drug Product Portfolio Table 117. DBV Technologies SA Recent Development Table 118. CSL Ltd Company Information Table 119. CSL Ltd Business Overview Table 120. CSL Ltd Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 121. CSL Ltd Hemophilia A Drug Product Portfolio Table 122. CSL Ltd Recent Development Table 123. Chugai Pharmaceutical Co Ltd Company Information Table 124. Chugai Pharmaceutical Co Ltd Business Overview Table 125. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 126. Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio Table 127. Chugai Pharmaceutical Co Ltd Recent Development Table 128. Catalyst Biosciences Inc Company Information Table 129. Catalyst Biosciences Inc Business Overview Table 130. Catalyst Biosciences Inc Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 131. Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio Table 132. Catalyst Biosciences Inc Recent Development Table 133. Bioverativ Inc Company Information Table 134. Bioverativ Inc Business Overview Table 135. Bioverativ Inc Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 136. Bioverativ Inc Hemophilia A Drug Product Portfolio Table 137. Bioverativ Inc Recent Development Table 138. BioMarin Pharmaceutical Inc Company Information Table 139. BioMarin Pharmaceutical Inc Business Overview Table 140. BioMarin Pharmaceutical Inc Hemophilia A Drug Sales (k units), Price (US$/unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 141. BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio Table 142. BioMarin Pharmaceutical Inc Recent Development Table 143. Key Raw Materials Table 144. Raw Materials Key Suppliers Table 145. Hemophilia A Drug Distributors List Table 146. Hemophilia A Drug Customers List Table 147. Research Programs/Design for This Report Table 148. Authors List of This Report Table 149. Secondary Sources Table 150. Primary Sources List of Figures Figure 1. Hemophilia A Drug Product Image Figure 2. Global Hemophilia A Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemophilia A Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemophilia A Drug Sales (2021-2032) & (k units) Figure 5. Global Hemophilia A Drug Average Price (US$/unit) & (2021-2032) Figure 6. Global Top 5 and 10 Hemophilia A Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. ATXF-8117 Image Figure 9. BAY-1093884 Image Figure 10. BIVV-001 Image Figure 11. BS-027125 Image Figure 12. Concizumab Image Figure 13. CSL-689 Image Figure 14. Others Image Figure 15. Global Hemophilia A Drug Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 16. Global Hemophilia A Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 17. Global Hemophilia A Drug Sales Market Share by Type (2021-2032) Figure 18. Global Hemophilia A Drug Revenue by Type (2021 VS 2025 VS 2032) & (k units) Figure 19. Global Hemophilia A Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 20. Global Hemophilia A Drug Revenue Market Share by Type (2021-2032) Figure 21. Clinic Image Figure 22. Hospital Image Figure 23. ASCs Image Figure 24. Global Hemophilia A Drug Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 25. Global Hemophilia A Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 26. Global Hemophilia A Drug Sales Market Share by Application (2021-2032) Figure 27. Global Hemophilia A Drug Revenue by Application (2021 VS 2025 VS 2032) & (k units) Figure 28. Global Hemophilia A Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 29. Global Hemophilia A Drug Revenue Market Share by Application (2021-2032) Figure 30. North America Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 31. North America Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 32. U.S. Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 33. Canada Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 34. Mexico Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 35. Europe Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 36. Europe Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 37. Germany Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 38. France Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 39. U.K. Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 40. Italy Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 41. Netherlands Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 42. Asia Pacific Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 43. Asia Pacific Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 44. China Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 45. Japan Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 46. South Korea Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 47. Southeast Asia Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 48. India Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 49. Australia Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 50. South America, Middle East and Africa Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 51. South America, Middle East and Africa Hemophilia A Drug Sales Market Share by Country (2021-2032) Figure 52. Brazil Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 53. South Africa Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 54. Saudi Arabia Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 55. Turkey Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 56. Argentina Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 57. UAE Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 58. Egypt Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 59. Chile Hemophilia A Drug Sales and Growth Rate (2021-2032) & (k units) Figure 60. Global Hemophilia A Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 61. Global Hemophilia A Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 62. North America Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Figure 63. North America Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Europe Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Figure 65. Europe Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Asia-Pacific Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Figure 67. Asia-Pacific Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. South America, Middle East and Africa Hemophilia A Drug Revenue (2021-2032) & (US$ Million) Figure 69. South America, Middle East and Africa Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. Hemophilia A Drug Value Chain Figure 71. Manufacturing Cost Structure Figure 72. Hemophilia A Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • ATXF-8117
  • BAY-1093884
  • BIVV-001
  • BS-027125
  • Concizumab
  • CSL-689
  • Others
Applications
  • Clinic
  • Hospital
  • ASCs
Companies covered
  • Bayer AG
  • mAbxience SA
  • LFB SA
  • Immusoft Corp
  • Idogen AB
  • Green Cross Corp
  • Expression Therapeutics LLC
  • EpiVax Inc
  • Dimension Therapeutics Inc
  • DBV Technologies SA
  • CSL Ltd
  • Chugai Pharmaceutical Co Ltd
  • Catalyst Biosciences Inc
  • Bioverativ Inc
  • BioMarin Pharmaceutical Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemophilia A Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemophilia A Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Hemophilia A Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Hemophilia A Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Hemophilia A Drug Market Dynamics
  1. 2.1 Hemophilia A Drug Industry Trends
  2. 2.2 Hemophilia A Drug Industry Drivers
  3. 2.3 Hemophilia A Drug Industry Opportunities and Challenges
  4. 2.4 Hemophilia A Drug Industry Restraints
3 Hemophilia A Drug Market by Manufacturers
  1. 3.1 Global Hemophilia A Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Hemophilia A Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Hemophilia A Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Hemophilia A Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Hemophilia A Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Hemophilia A Drug Manufacturers, Product Type & Application
  7. 3.7 Global Hemophilia A Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Hemophilia A Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Hemophilia A Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Hemophilia A Drug Tier 1, Tier 2, and Tier 3
4 Hemophilia A Drug Market by Type
  1. 4.1 Hemophilia A Drug Type Introduction
  2. 4.1.1 ATXF-8117
  3. 4.1.2 BAY-1093884
  4. 4.1.3 BIVV-001
  5. 4.1.4 BS-027125
  6. 4.1.5 Concizumab
  7. 4.1.6 CSL-689
  8. 4.1.7 Others
  9. 4.2 Global Hemophilia A Drug Sales by Type
  10. 4.2.1 Global Hemophilia A Drug Sales by Type (2021 VS 2025 VS 2032)
  11. 4.2.2 Global Hemophilia A Drug Sales by Type (2021-2032)
  12. 4.2.3 Global Hemophilia A Drug Sales Market Share by Type (2021-2032)
  13. 4.3 Global Hemophilia A Drug Revenue by Type
  14. 4.3.1 Global Hemophilia A Drug Revenue by Type (2021 VS 2025 VS 2032)
  15. 4.3.2 Global Hemophilia A Drug Revenue by Type (2021-2032)
  16. 4.3.3 Global Hemophilia A Drug Revenue Market Share by Type (2021-2032)
5 Hemophilia A Drug Market by Application
  1. 5.1 Hemophilia A Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 ASCs
  5. 5.2 Global Hemophilia A Drug Sales by Application
  6. 5.2.1 Global Hemophilia A Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hemophilia A Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Hemophilia A Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Hemophilia A Drug Revenue by Application
  10. 5.3.1 Global Hemophilia A Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hemophilia A Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Hemophilia A Drug Revenue Market Share by Application (2021-2032)
6 Global Hemophilia A Drug Sales by Region
  1. 6.1 Global Hemophilia A Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemophilia A Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Hemophilia A Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Hemophilia A Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Hemophilia A Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Hemophilia A Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Hemophilia A Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Hemophilia A Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Hemophilia A Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Hemophilia A Drug Revenue by Region
  1. 7.1 Global Hemophilia A Drug Revenue by Region
  2. 7.1.1 Global Hemophilia A Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Hemophilia A Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Hemophilia A Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Hemophilia A Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Hemophilia A Drug Revenue (2021-2032)
  8. 7.2.2 North America Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Hemophilia A Drug Revenue (2021-2032)
  11. 7.3.2 Europe Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Hemophilia A Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Hemophilia A Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Hemophilia A Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Bayer AG
  2. 8.1.1 Bayer AG Company Information
  3. 8.1.2 Bayer AG Business Overview
  4. 8.1.3 Bayer AG Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Bayer AG Hemophilia A Drug Product Portfolio
  6. 8.1.5 Bayer AG Recent Developments
  7. 8.2 mAbxience SA
  8. 8.2.1 mAbxience SA Company Information
  9. 8.2.2 mAbxience SA Business Overview
  10. 8.2.3 mAbxience SA Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 mAbxience SA Hemophilia A Drug Product Portfolio
  12. 8.2.5 mAbxience SA Recent Developments
  13. 8.3 LFB SA
  14. 8.3.1 LFB SA Company Information
  15. 8.3.2 LFB SA Business Overview
  16. 8.3.3 LFB SA Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 LFB SA Hemophilia A Drug Product Portfolio
  18. 8.3.5 LFB SA Recent Developments
  19. 8.4 Immusoft Corp
  20. 8.4.1 Immusoft Corp Company Information
  21. 8.4.2 Immusoft Corp Business Overview
  22. 8.4.3 Immusoft Corp Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Immusoft Corp Hemophilia A Drug Product Portfolio
  24. 8.4.5 Immusoft Corp Recent Developments
  25. 8.5 Idogen AB
  26. 8.5.1 Idogen AB Company Information
  27. 8.5.2 Idogen AB Business Overview
  28. 8.5.3 Idogen AB Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Idogen AB Hemophilia A Drug Product Portfolio
  30. 8.5.5 Idogen AB Recent Developments
  31. 8.6 Green Cross Corp
  32. 8.6.1 Green Cross Corp Company Information
  33. 8.6.2 Green Cross Corp Business Overview
  34. 8.6.3 Green Cross Corp Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Green Cross Corp Hemophilia A Drug Product Portfolio
  36. 8.6.5 Green Cross Corp Recent Developments
  37. 8.7 Expression Therapeutics LLC
  38. 8.7.1 Expression Therapeutics LLC Company Information
  39. 8.7.2 Expression Therapeutics LLC Business Overview
  40. 8.7.3 Expression Therapeutics LLC Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Expression Therapeutics LLC Hemophilia A Drug Product Portfolio
  42. 8.7.5 Expression Therapeutics LLC Recent Developments
  43. 8.8 EpiVax Inc
  44. 8.8.1 EpiVax Inc Company Information
  45. 8.8.2 EpiVax Inc Business Overview
  46. 8.8.3 EpiVax Inc Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 EpiVax Inc Hemophilia A Drug Product Portfolio
  48. 8.8.5 EpiVax Inc Recent Developments
  49. 8.9 Dimension Therapeutics Inc
  50. 8.9.1 Dimension Therapeutics Inc Company Information
  51. 8.9.2 Dimension Therapeutics Inc Business Overview
  52. 8.9.3 Dimension Therapeutics Inc Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Dimension Therapeutics Inc Hemophilia A Drug Product Portfolio
  54. 8.9.5 Dimension Therapeutics Inc Recent Developments
  55. 8.10 DBV Technologies SA
  56. 8.10.1 DBV Technologies SA Company Information
  57. 8.10.2 DBV Technologies SA Business Overview
  58. 8.10.3 DBV Technologies SA Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 DBV Technologies SA Hemophilia A Drug Product Portfolio
  60. 8.10.5 DBV Technologies SA Recent Developments
  61. 8.11 CSL Ltd
  62. 8.11.1 CSL Ltd Company Information
  63. 8.11.2 CSL Ltd Business Overview
  64. 8.11.3 CSL Ltd Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 CSL Ltd Hemophilia A Drug Product Portfolio
  66. 8.11.5 CSL Ltd Recent Developments
  67. 8.12 Chugai Pharmaceutical Co Ltd
  68. 8.12.1 Chugai Pharmaceutical Co Ltd Company Information
  69. 8.12.2 Chugai Pharmaceutical Co Ltd Business Overview
  70. 8.12.3 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Chugai Pharmaceutical Co Ltd Hemophilia A Drug Product Portfolio
  72. 8.12.5 Chugai Pharmaceutical Co Ltd Recent Developments
  73. 8.13 Catalyst Biosciences Inc
  74. 8.13.1 Catalyst Biosciences Inc Company Information
  75. 8.13.2 Catalyst Biosciences Inc Business Overview
  76. 8.13.3 Catalyst Biosciences Inc Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Catalyst Biosciences Inc Hemophilia A Drug Product Portfolio
  78. 8.13.5 Catalyst Biosciences Inc Recent Developments
  79. 8.14 Bioverativ Inc
  80. 8.14.1 Bioverativ Inc Company Information
  81. 8.14.2 Bioverativ Inc Business Overview
  82. 8.14.3 Bioverativ Inc Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bioverativ Inc Hemophilia A Drug Product Portfolio
  84. 8.14.5 Bioverativ Inc Recent Developments
  85. 8.15 BioMarin Pharmaceutical Inc
  86. 8.15.1 BioMarin Pharmaceutical Inc Company Information
  87. 8.15.2 BioMarin Pharmaceutical Inc Business Overview
  88. 8.15.3 BioMarin Pharmaceutical Inc Hemophilia A Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 BioMarin Pharmaceutical Inc Hemophilia A Drug Product Portfolio
  90. 8.15.5 BioMarin Pharmaceutical Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hemophilia A Drug Value Chain Analysis
  2. 9.1.1 Hemophilia A Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hemophilia A Drug Production Mode & Process
  6. 9.2 Hemophilia A Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hemophilia A Drug Distributors
  9. 9.2.3 Hemophilia A Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst